Generic Name: latanoprost
Brand Name: Monoprost
Manufacturer: Laboratoires Théa
Therapeutic Area: glaucoma and ocular hypertension
Indications: glaucoma and ocular hypertension
Submission Type: Initial
Project Status: Complete
Biosimilar: No
Date Recommendation Issued: April 24, 2018
Recommendation Type: Reimburse with clinical criteria and/or conditions
Fee Schedule: Schedule A
Key Milestones2 | |
|---|---|
| Call for patient input posted | September 26, 2017 |
| Patient group input closed | November 15, 2017 |
| Clarification: - No patient input submission received | |
| Submission received | October 25, 2017 |
| Submission accepted for review | November 08, 2017 |
| Review initiated | November 09, 2017 |
| Draft CDR review report(s) sent to applicant | February 01, 2018 |
| Comments from applicant on draft CDR review report(s) received | February 12, 2018 |
| Redaction requests from applicant on draft CDR review report(s) received | February 20, 2018 |
| CDR review team's comments on draft CDR review report(s) sent to applicant | March 09, 2018 |
| Canadian Drug Expert Committee (CDEC) meeting | March 21, 2018 |
| CDEC recommendation & redacted CDR review report(s) sent to applicant and drug plans | April 03, 2018 |
| Embargo period ended and validation of redacted CDR review report(s) received | April 17, 2018 |
| CDEC Final Recommendation issued to applicant and drug plans | April 24, 2018 |
| CDEC Final Recommendation posted | April 27, 2018 |
| Final CDR review report(s) and patient input posted | May 17, 2018 |